United States
Print page content Print
Increase text size Decrease text size
Text Size
Eff Top Banner

A single injection begins reducing itch within 1 day and continues working for a full month

OVER 80% OF DOGS HAD SUCCESSFUL PRURITUS REDUCTION AT DAY 3

At day 3, greater than 80% of dogs administered Canine Atopic Dermatitis lmmunotherapeutic* achieved treatment success, predefined as owner-assessed ≥20mm reduction in pruritus as scored on the pruritus Visual Analog Scale (VAS).1†

Efficacy chart 1

Mean pruritus scores were very mild to mild starting at day 1 and continuing for a full month

At day 42, owner assessment of pruritus VAS scores remained mild at 37.6 mm (mean baseline, 71.0 mm) for dogs receiving a 2 mg/kg dose of Canine Atopic Dermatitis Immunotherapeutic.1*

Efficacy chart 2

*This product license is conditional. Efficacy and potency test studies in progress.

VAS is an owner-assessed scale that measures itch along a continuum from normal dog (no itch) to extremely severe itch, using numbers from 0-100. VAS scoring instruments were given to owners, accompanied by explanations of how to rank itch, based on the behavior of the animal. Owners ranked itch daily.

Reference: 1. Data on file, Study Report No. C863R-US-12-018. Zoetis LLC.

Eff Bottom Banner

Skin condition begins to improve within 7 days

SKIN CONDITION SCORE REDUCTION WAS SIGNIFICANT AT DAY 14

Significantly more dogs treated with Canine Atopic Dermatitis Immunotherapeutic achieved treatment success (at least a 50% reduction from baseline in CADESI-03) compared to dogs treated with placebo from day 14 of the study.

Efficacy chart 3

Skin condition score reduction was maintained through day 28

Significant improvement in skin condition was noted at the first visit on day 7 (p≤0.05). At day 28, there was a nearly 50% decrease in mean CADESI-03 scores for dogs administered Canine Atopic Dermatitis Immunotherapeutic* (73.7) compared to dogs administered placebo (121.9) (mean baseline for all dogs, 153.9).1

Efficacy chart 4

*This product license is conditional. Efficacy and potency test studies in progress.

Canine Atopic Dermatitis Extent and Severity Index. CADESI-03 skin condition assessment consisted of an evaluation of erythema, lichenification, excoriation and alopecia at 62 body sites.

Reference: 1. Data on file, Study Report No. C863R-US-12-018. Zoetis LLC.


All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2016 Zoetis Services LLC. All rights reserved. CYT-00078